Relevant bibliographies by topics / Meropenem

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Meropenem'

Author: Grafiati
Published: 4 June 2021
Last updated: 7 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Meropenem.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Meropenem"

1

Fawaz, Sarah, Stephen Barton, Laura Whitney, Julian Swinden, and Shereen Nabhani-Gebara. "Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion." Hospital Pharmacy 54, no. 3 (May 30, 2018): 190–96. http://dx.doi.org/10.1177/0018578718779009.

Full text
Abstract:
Objective: Meropenem is a parenteral carbapenem antibiotic which has a broad spectrum of activity against aerobes and anaerobes. Meropenem’s bactericidal activity is determined by the time during which meropenem concentration remains above the minimal inhibition concentration (MIC) during the dosing interval. Thus, prolonged infusion is the optimal way to maximize the time-dependant activity. However, studies to date have shown that carbapenems and in particular, meropenem, are relatively unstable in solution. The aims of this study were therefore (1) to establish the effects of temperature on the concentration of a generic brand reconstituted meropenem solution and (2) to determine whether 24-hour continuous infusion is possible without concentrations dropping below the recommended 90%. Method: Preliminary examination was carried out by the means of nuclear magnetic resonance (NMR) spectroscopy. Meropenem was subsequently assayed using high-performance liquid chromatography (HPLC). The method was developed and validated in compliance with International Council for Harmonisation (ICH) guidelines. Meropenem’s stability was examined at two temperatures 22°C and 33°C to mimic average and high temperature in hospital wards. Solutions were prepared aseptically at the clinically relevant concentration. Results: NMR results obtained showed an increase in open ring methyl groups peak intensity, indicating that meropenem begins to degrade upon dissolution (d=1.05 and 1.25). Results obtained from quantitative HPLC confirm that meropenem concentrations dropped to 90% of initial concentration at 7.4 hours and 5.7 hours at 22°C and 33°C, respectively. Conclusion: Although results obtained indicate that meropenem should not be continuously infused over 24 hours, it is possible that meropenem could be continuously infused for at least 7 hours if temperature does not exceed 22°C and for 5 hours if temperature does not exceed 33°C.
APA, Harvard, Vancouver, ISO, and other styles
2

Чеботарь, И. В., Ю. А. Бочарова, А. В. Чаплин, Т. А. Савинова, Ю. А. Василиадис, and Н. А. Маянский. "Mutatsionnyye osnovy formirovaniya ustoychivosti k meropenemu u Pseudomonas aeruginosa." Вестник Российского государственного медицинского университета, no. 2022(6) (December 2022): 64–69. http://dx.doi.org/10.24075/vrgmu.2022.063.

Full text
Abstract:
Rezistentnyye k karbapenemam shtammy Pseudomonas aeruginosa rastsenivayut v kachestve kriticheski opasnykh patogenov pervogo urovnya prioriteta. Rasshifrovka mekhanizmov formirovaniya ustoychivosti k karbapenemam yavlyayetsya aktual'noy zadachey sovremennoy meditsinskoy nauki. Tsel'yu raboty bylo opisat' raznoobraziye i zakrepleniye mutatsiy, assotsiirovannykh s formirovaniyem karbapenemrezistentnosti v protsesse adaptatsii P. aeruginosa k povyshayushchimsya kontsentratsiyam meropenema. Ob"yektami issledovaniya byli izolyaty P. aeruginosa, poluchennyye pri roste referentnogo shtamma P. aeruginosa ATCC 27853 v gradiyente vozrastayushchikh kontsentratsiy meropenema. Otsenku chuvstvitel'nosti izolyatov k meropenemu vypolnyali pri pomoshchi ye-testov (epsilometricheskiy metod) s meropenemom i pri pomoshchi metoda dilyutsii antibiotika v agare. Genomy izolyatov byli sekvenirovany na polnogenomnom sekvenatore MGISEQ-2000. Poluchennyye rezul'taty pokazali, chto formirovaniye vysokikh urovney rezistentnosti k meropenemu u P. aeruginosa v eksperimente proiskhodit v korotkiye sroki (6 sutok). Evolyutsiya rezistentnosti sopryazhena s protsessom klonirovaniya, pri kotorom proiskhodit vozniknoveniye mnozhestva klonov s razlichnymi genotipami. Osnovoy klonirovaniya yavlyayetsya mutagenez, v kotoryy vovlecheny 11 genov, vklyuchaya oprD, pbuE, nalD, nalC, spoT, mlaA, mexD, mexR, oprM, mraY, pbp3. Chast' obrazovavshikhsya klonov, nezavisimo ot urovnya ikh rezistentnosti k meropenemu, ne poluchayut progressivnogo razvitiya i vytesnyayutsya boleye uspeshnymi klonami.
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Meropenem." Reactions Weekly &NA;, no. 1196 (April 2008): 29. http://dx.doi.org/10.2165/00128415-200811960-00084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wiseman, Lynda R., Antona J. Wagstaff, Rex N. Brogden, and Harriet M. Bryson. "Meropenem." Drugs 50, no. 1 (July 1995): 73–101. http://dx.doi.org/10.2165/00003495-199550010-00007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

&NA;. "Meropenem." Reactions Weekly &NA;, no. 1401 (May 2012): 24. http://dx.doi.org/10.2165/00128415-201214010-00094.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

&NA;. "Meropenem." Reactions Weekly &NA;, no. 1404 (June 2012): 29. http://dx.doi.org/10.2165/00128415-201214040-00097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hurst, Miriam, and Harriet M. Lamb. "Meropenem." Drugs 59, no. 3 (March 2000): 653–80. http://dx.doi.org/10.2165/00003495-200059030-00016.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lowe, Matthew N., and Harriet M. Lamb. "Meropenem." Drugs 60, no. 3 (September 2000): 619–46. http://dx.doi.org/10.2165/00003495-200060030-00010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Baldwin, Claudine M., Katherine A. Lyseng-Williamson, and Susan J. Keam. "Meropenem." Drugs 68, no. 6 (2008): 803–38. http://dx.doi.org/10.2165/00003495-200868060-00006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

&NA;. "Meropenem." Reactions Weekly &NA;, no. 871 (September 2001): 9. http://dx.doi.org/10.2165/00128415-200108710-00027.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Meropenem"

1

Mendez, Andreas Sebastian Loureiro. "Estudo de estabilidade do antibiótico meropenem." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2007. http://hdl.handle.net/10183/28512.

Full text
Abstract:
A estabilidade de medicamentos constitui um tema atual e de grande importância no meio científico. Tem sido constantemente abordada em estudos direcionados à avaliação da qualidade das preparações farmacêuticas. O meropenem, um antibiótico carbapenêmico de amplo espectro de ação, é utilizado como um importante recurso terapêutico para o tratamento de infecções graves. Por ser um agente antimicrobiano ativo e eficaz, de uso clínico em muitos países, tornase necessária a pesquisa mais aprofundada de sua estabilidade, propiciando um maior entendimento dos aspectos que podem influenciar na sua manipulação e armazenamento. O presente trabalho objetiva a avaliação da estabilidade do meropenem em condições de degradação forçada, contemplando a determinação da cinética de degradação, o isolamento e identificação de produtos de decomposição e a determinação da citotoxicidade das amostras degradadas e dos produtos isolados. Amostras de meropenem pó para solução injetável (500 mg) e solução reconstituída em água (50 mg/mL) foram submetidas à degradação térmica em diferentes temperaturas. Para a decomposição ácido-base, soluções aquosas de meropenem a 1,0 mg/mL foram preparadas em HCl 0,1 M e NaOH 0,1 M, e estocadas a 25 °C. As amostras foram analisadas por cromatografia líquida de alta eficiência, em sistema de fase reversa. Para o ensaio de determinação cinética, as amostras submetidas à maior temperatura de degradação foram também analisadas por ensaio microbiológico – método de difusão em ágar-cilindros em placas. O isolamento do produto de degradação térmica foi efetuado através da combinação das técnicas de cromatografia em coluna e cromatografia em camada delgada preparativa. Para o produto oriundo de catálise básica, a identificação foi efetuada diretamente na amostra degradada, não havendo a necessidade de prévio isolamento. A elucidação estrutural dos produtos de degradação foi realizada por ressonância magnética nuclear e espectrometria de massas. As amostras degradadas e o produto de catálise básica foram avaliados in vitro quanto ao potencial citotóxico frente a células mononucleares. Para determinação da viabilidade celular, os conteúdos celulares foram avaliados por citometria de fluxo. Os resultados dos ensaios de cinética química indicaram que o meropenem sofre decomposição térmica seguindo reação de primeira ordem. As amostras degradadas apresentaram uma acentuada redução de teor, com formação de produtos de degradação. As técnicas cromatográficas de purificação utilizadas permitiram o isolamento de um produto oriundo da degradação térmica da solução reconstituída. A identificação demonstrou que o mesmo teve uma modificação estrutural extensa, gerada a partir de reações de decomposição passíveis de ocorrer para o derivado carbapenêmico avaliado. Para o produto de degradação básica, verificou-se o rompimento do anel β-lactâmico, em reação característica destes compostos. A avaliação preliminar da citotoxicidade indicou que as amostras ensaiadas apresentam toxicidade celular in vitro após 48 horas de incubação, fornecendo indícios de necessidade de atenção para este aspecto. A totalidade dos resultados obtidos neste trabalho permite a conclusão de que a estabilidade do meropenem é um tema de grande relevância e deve ser considerada na hora da manipulação do produto, de modo a evitar problemas de qualidade oriundos de amostras degradadas e seus produtos de degradação.
The stability of pharmaceuticals is a current and important subject in the scientific field. It has been frequently cited in studies related with the quality evaluation of pharmaceutical preparations. Meropenem, a carbapenemic antibiotic with broad spectrum, is used as an important therapeutic agent for the treatment of several infections. Since it is an active and effective antimicrobial, used in many countries, it is necessary the complete research about its stability, providing more knowledge about the aspects that could influence in its handle and storage. The aim of this work is the evaluation of meropenem stability in forced degradation conditions, including the determination of degradation kinetics, the isolation and identification of decomposition products and the citotoxicity evaluation of degraded samples and isolated products. Meropenem powder for injection (500 mg) and reconstituted solution in water (50 mg ml-1) were submitted to thermal degradation. For acid-basic decomposition, meropenem aqueous solution at 1.0 mg ml-1 were prepared in HCl 0.1 M and NaOH 0.1 M, and stored at 25 °C. The samples were analysed by high performance liquid chromatography, in reverse phase system. In the kinetics determination, the samples stored at 45 °C and 90 °C were also evaluated by microbiological assay, applying the cylinder-plate method. The isolation of thermal degradation product was carried out by column chromatography and preparative thin layer chromatography. For the product obtained through basic catalysis, the identification was done directly in the degraded sample, without previous isolation. The structural elucidation of degradation products was performed by nuclear magnetic ressonance and mass spectrometry. The degraded samples and basic catalysis product were evaluated with respect to citotoxic potential in vitro against mononuclear cells. The cellular viability was determined by flow citometry. The results of chemical kinetics indicated that thermal decomposition of meropenem is described by first order reaction. The degraded samples showed a significant reduction in the potency, with formation of degradation products. The chromatographic purification techniques allowed the isolation of one thermal degradation product. For the basic degradation product, it was verified the hidrolysis of β-lactam ring, in a caracterisitc reaction for these compounds. The preliminary citotoxicity evaluation indicated that samples were toxic after 48 hours. The results obtained in this work allowed to conclude that the stability of meropenem is a subject of great importance and should be considered in the handle of the product, in order to avoid quality problems from degraded samples and degradation products.
APA, Harvard, Vancouver, ISO, and other styles
2

Abbott, Stacey, Georgina Rubal-Peace, and Jamie Natkowski. "Appropriate Use of Meropenem: A Pharmacy Intervention." The University of Arizona, 2014. http://hdl.handle.net/10150/614200.

Full text
Abstract:
Class of 2014 Abstract
Specific Aims: The primary objective was to determine the effectiveness of a criteria-based antibiotic order form (CBAOF) at increasing appropriate meropenem use at University of Arizona Medical Center –South Campus (UAMCSC). The secondary objective was to assess any cost savings associated with increased appropriate meropenem use. Methods: A retrospective chart review of patients (n = 133) meeting inclusion criteria at UAMCSC during the pre and post-intervention periods was conducted. Outcomes included appropriate empiric use of meropenem, appropriate treatment of a known pathogen use of meropenem, appropriate dose and frequency of meropenem, appropriate antibiotic streamlining after culture and susceptibility report, and meropenem acquisition costs. Main Results: Appropriate empiric use of meropenem was significantly higher after the implementation of the CBAOF (100% vs. 65.8%, p = 0.002). Although not statistically significant, the post-intervention group had more patients meeting the criteria for appropriate use of meropenem for a known pathogen than the pre-intervention group (50% vs. 40%, p = 0.809). There were no differences between the pre and post-intervention groups with respect to appropriate dose of meropenem or appropriate frequency. After the implementation of the CBAOF there were significantly more patients who received antibiotic streamlining within 24 hours of culture and susceptibility reports (12.5% vs. 48.7%, p = 0.002). Drug acquisition costs for meropenem were reduced by approximately $30,000 after CBAOF implementation. Conclusion: The CBAOF was effective at increasing appropriate empiric meropenem use and decreasing meropenem acquisition costs at UAMCSC.
APA, Harvard, Vancouver, ISO, and other styles
3

Wolken, Kathryn, and Velliyur Viswesh. "The Appropriateness of Antibiotic Therapy in Patients Initiated on Meropenem in a University-Affiliated Hospital." The University of Arizona, 2011. http://hdl.handle.net/10150/623557.

Full text
Abstract:
Class of 2011 Abstract
OBJECTIVES: To determine the appropriateness of antimicrobial therapy in patients initiated on empiric meropenem therapy. METHODS: Adult patients prescribed empiric meropenem therapy between January 1, 2010 and March 31, 2010 at a tertiary care, academic medical center were included. Data collected included site of infection, culture and susceptibility data, risk factors for multi-drug resistant organisms, and changes in antimicrobial therapy during the first seven days after meropenem therapy was initiated. Demographic variables included age, sex, weight, and race. RESULTS: RESULTS: A total of 89 patients were included in the study analysis. Initial culture(s) was obtained before administration of antibiotics in only 58% of patients. During the first 24 hours of admission, four or more different antibiotics were prescribed in 26% of patients often with overlapping spectrums of activity. The majority of patients received meropenem for either less than 1 day or greater than 4 days. CONCLUSION: The primary issues identified with appropriate antibiotic prescribing involved the timing of cultures, and multiple changes in antibiotic therapy without culture-driven reasoning.
APA, Harvard, Vancouver, ISO, and other styles
4

MacKenzie, Fiona M. "Investigations of the postantibiotic effect and related antibacterial activity of meropenem." Thesis, Robert Gordon University, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.239961.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lima, Camila Nayane de Carvalho. "Convulsant carbapenems potential of different models in experimental convulsion: benchmarking, behavioral and neurochemical." Universidade Federal do CearÃ, 2011. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=9563.

Full text
Abstract:
CoordenaÃÃo de AperfeiÃoamento de NÃvel Superior
Epilepsy is the most common neurological disorder, affecting 50 million people worldwide, 40 million of them in developed countries. People of all races, genders, socioeconomic conditions and regions are affected. The pilocarpine (P400) is a cholinergic agonist characterized by inducing seizures evolving to status epilepticus, similar to human temporal lobe epilepsy. The pentylenetetrazole (PTZ) is a GABA antagonist that mimics the small-mal seizures (absence seizure) and tonic-clonic seizures in humans. The strychnine is a potent convulsant and acts mainly as a selective antagonist of postsynaptic inhibition mediated by glycine. Its main action is to increase the excitability of the spinal reflex . The convulsant picrotoxin is an agent that blocks chloride channels activated by gamma-aminobutyric acid. Convulsant agents were administered intraperitoneally, 10 minutes after intravenous administration of carbapenÃmcios With the development of this work, we found that pretreatment with imipenem or meropenem interfere with various neurotransmitter systems when animals are subjected to seizures induced by pilocarpine at a dose of 400mg/kg, 55mg/Kg at a dose of pentylenetetrazole, strychnine and picrotoxin 10mg/Kg 2mg/kg. This has been evidenced by increasing levels of excitatory amino acids such as glutamate and on the other hand, a decrease in levels of inhibitory amino acids such as GABA reinforcing the existence of a possible modulatory pathway of these amino acids in control and development of seizure occurs when pre-treatment with imipenem or meropenem.
Epilepsia à o mais freqÃente distÃrbio neurolÃgico, atingindo 50 milhÃes de pessoas no mundo, 40 milhÃes delas em paÃses desenvolvidos. Pessoas de todas as raÃas, sexos, condiÃÃes socioeconÃmicas e regiÃes sÃo acometidas. A pilocarpina (P400) à um agonista colinÃrgico que se caracteriza por induzir convulsÃes que evoluem para status epilÃpticus, similar à epilepsia do lobo temporal humana. O pentilenotetrazol (PTZ) à um antagonista GABA que mimetiza convulsÃes do pequeno-mal (crise de ausÃncia) e do tipo tÃnico-clÃnico em humanos. A estricnina à um potente convulsivante e atua, principalmente, como antagonista competitivo seletivo da inibiÃÃo pÃs-sinÃptica mediada pela glicina. Sua principal aÃÃo à o aumento da excitabilidade reflexa da medula. A picrotoxina à um agente convulsivante que bloqueia os canais de cloro ativados pelo Ãcido gama-aminobutÃrico. Os agentes convulsivantes foram administrados intraperitonialmente, apÃs 10 minutos da administraÃÃo intravenosa dos carbapenÃmcios Com o desenvolvimento deste trabalho, podemos observar que o prÃ-tratamento com imipenem ou meropenem interfere com vÃrios sistemas de neurotransmissores quando os animais sÃo submetidos à convulsÃo induzida pela pilocarpina na dose de 400mg/kg, pentilenotetrazol na dose de 55mg/Kg, estricnina 2mg/Kg e picrotoxina 10mg/Kg. Tal efeito foi evidenciado atravÃs do aumento nos nÃveis de aminoÃcidos excitatÃrios como o glutamato e, por outro lado, uma diminuiÃÃo nos nÃveis de aminoÃcidos inibitÃrios como o GABA reforÃando a existÃncia de uma possÃvel via modulatÃria desses aminoÃcidos no controle e desenvolvimento de crises epilÃpticas quando ocorre o prÃ-tratamento com imipenem/cilastatina ou meropenem.
APA, Harvard, Vancouver, ISO, and other styles
6

Gilcher, Thomas [Verfasser]. "Pharmakokinetik von Linezolid und Meropenem bei Intensivpatienten mit kontinuierlicher Nierenersatztherapie / Thomas Gilcher." Mainz : Universitätsbibliothek der Johannes Gutenberg-Universität Mainz, 2016. http://d-nb.info/1225685389/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

MASCENA, Guilherme Veras. "Resposta terapêutica de ratos com peritonite fecal submetidos ao uso de meropenem intravenoso." Universidade Federal de Pernambuco, 2014. https://repositorio.ufpe.br/handle/123456789/17454.

Full text
Abstract:
Submitted by Isaac Francisco de Souza Dias (isaac.souzadias@ufpe.br) on 2016-07-18T18:44:57Z No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) TESE GUILHERME VERAS 19 OUT-MM.pdf: 2315237 bytes, checksum: dfde31585678c4be265e3df28d667cb7 (MD5)
Made available in DSpace on 2016-07-18T18:44:57Z (GMT). No. of bitstreams: 2 license_rdf: 1232 bytes, checksum: 66e71c371cc565284e70f40736c94386 (MD5) TESE GUILHERME VERAS 19 OUT-MM.pdf: 2315237 bytes, checksum: dfde31585678c4be265e3df28d667cb7 (MD5) Previous issue date: 2014-11-10
Objetivo: Avaliar o resultado do tratamento com meropenem intravenoso de peritonite grave em ratos com diferentes idades. Métodos: Trinta ratos Wistar estratificados em três grupos: grupo I - seis meses de idade; grupo II - 12 meses de idade; e grupo III - 18 meses de idade, submetidos à indução de peritonite autógena com suspensão de fezes a 10% (6ml/kg de rato), foram tratados com meropenem intravenoso na dose única de 40mg/Kg de rato. Os animais que sobreviveram foram acompanhados por 45 dias. Os parâmetros das variáveis quantitativas foram expressos por suas médias e pelo erro padrão da média (EPM) e p < 0,05 foi usado para rejeitar a hipótese de nulidade. O estudo foi aprovado pelo Comitê de Ética no Uso de Animais. Resultados: A mortalidade foi igual para os grupos I e II (10%). No grupo III, 4 dos 10 animais morreram nas primeiras 24 horas e mais 4 até 48 horas. De interesse, mesmo os ratos jovens que sobreviveram apresentaram abscessos residuais nas cavidades abdominal e torácica, embora tenham evoluído com vida quase normal. Com exceção de um rato do grupo I, todos os animais sobreviventes dos três grupos apresentaram hemocultura negativa. Conclusões: O tratamento da peritonite fecal autógena grave com meropenem intravenoso alcançou bons resultados em ratos com seis e doze meses de idade, mesmo considerando os abscessos residuais na cavidade abdominal e torácica. No entanto, 8 dos 10 ratos idosos (80%) não conseguiram superar o desafio infeccioso inicial, provando que o envelhecimento é um fator de risco muito importante no prejuízo da resposta imunológica. Assim, a sepse continua a ser uma situação desafiadora, especialmente em idosos.
Purpose: To evaluate the treatment outcome of severe peritonitis treated with intravenous meropenem in rats with increasing age. Methods: Thirty Wistar rats stratified in three groups: group I – six month-old; group II – 12 month-old; and group III – 18 month-old, underwent autogenously fecal peritonitis (6 ml/kg rat), were treated with intravenous meropenem at a single dose of 40 mg/kg of rat. The survival animals were followed-up for 45 days. The parameters of the quantitative variables were expressed as means and standard error of the mean (SEM) and p <0.05 was used to reject the null hypothesis. The study was approved by the Ethics Committee on Animal Use. Results: Mortality was similar for groups I and II (10%). In group III, 4 of 10 animals died within the first 24 hours and 4 more up to 48 hours. Of interest, even young rats that survived had residual abscesses in both the abdominal and thoracic cavities, although they were living an almost normal life. Except for one rat in group I, all surviving animals of the three groups showed a negative blood culture. Conclusions: The outcome of severe autogenously peritonitis in rats treated with intravenous meropenem in rats was good in animal with ages of six and twelve months, even considering the residual abscesses in the abdominal and chest cavities. However, 8 of 10 elderly rats (80%) could not overcome the initial infectious challenge, proving that aging is an important risk factor in the loss of immune response. Thus, sepsis continues to be a challenging situation, especially in the
APA, Harvard, Vancouver, ISO, and other styles
8

Hands, Catherine Lauren. "Relationships between zinc and meropenem resistance in the natural environment and experimental bioreactors." Thesis, University of Newcastle upon Tyne, 2016. http://hdl.handle.net/10443/3512.

Full text
Abstract:
The efficacy of antibiotics is being challenged by the emergence of bacteria resistant to antibiotics (AR), both in natural and clinical settings. Antibiotics and associated AR can be transmitted and dispersed via environmental bacteria, however AR might also be conferred in situ, without antibiotic pressure. For example, release of metal-bearing wastes to natural environments can proliferate AR. An important case is the influence of zinc (Zn) contamination on environmental AR, which increased tetracycline and quinolone resistance in wastewater isolates. However, how Zn might influence AR to therapeutically critical carbapenem antibiotics, including meropenem is unknown, which fuelled this study. Here the percentage of total isolates resistant to Zn, meropenem and-or both, were compared and assessed in varied microbial communities from natural environments and bioreactors. Overall, Zn levels, and Zn and meropenem resistant isolates correlated in all settings. For example, the abundance of combined meropenem plus Zn resistant isolates was significantly higher in high Zn (South Tyne) versus low Zn (North Tyne) sediments, and correlated with soluble and total Zn levels (p-value < 0.010 and p-value < 0.050, respectively), implying that acquired Zn resistance might confer meropenem resistance to isolates. In parallel, batch reactors seeded with North and South Tyne sediments, and amended with 2.00 mg/L (low) and 100 mg/L (high) Zn (2 x 2 design), showed increased relative percent meropenem resistant isolates in reactors with high (South Tyne: 21.0%; North Tyne: 31.0%) versus low Zn (South Tyne: 17.0%; North Tyne: 14.0%), whereas, sediment source (South vs North Tyne) was not important. Further, sediment soluble Zn levels significantly correlated with meropenem resistant isolates in all reactors, suggesting that the observed meropenem resistance was a possible “side effect” of cellular defence against Zn toxicity. Similar results were seen in Zn and meropenem-amended rotating tubular reactors treating domestic wastewater. Reactors dosed with 2.00 mg/L meropenem plus 100 mg/L Zn showed combined resistance in 51.0% of reactor effluent isolates, whereas only 24.0% displayed combined resistance with amendments of 2.00 mg/L meropenem and 20.0 mg/L Zn. Overall, elevated Zn levels significantly increased Zn, meropenem and combined resistance in isolates from sediments, batch reactors and tubular reactors. Therefore, one can conclude Zn levels impact meropenem resistance, although evidence suggest meropenem resistance is most apparent when Zn is present and resistance can be lost when Zn is removed, suggesting cross resistance mechanisms.
APA, Harvard, Vancouver, ISO, and other styles
9

Lohmeier, Stefanie [Verfasser]. "Der Einfluss einer blutspiegelgestützten Therapie mit Meropenem bei Intensivpatienten mit schweren Infektionen / Stefanie Lohmeier." Magdeburg : Universitätsbibliothek, 2018. http://d-nb.info/1171899742/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Loos, Stefanie [Verfasser]. "Etablierung und Durchführung des Therapeutischen Drug Monitorings unter kontinuierlicher Antibiotikagabe am Beispiel von Meropenem / Stefanie Loos." Ulm : Universität Ulm, 2018. http://d-nb.info/1169747124/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Meropenem"

1

Wilson, A. P. R., and Preet Panesar. Antimicrobial drugs in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0053.

Full text
Abstract:
The pharmacokinetics of antimicrobials are altered in critically-ill patients, particularly in the presence of renal or hepatic failure. Maintaining a choice or diversity of antibiotics is important due to the emergence of resistance. Antibiotic use should also be kept to the minimum and local protocols need to be established. For community-acquired infection, co-amoxiclav or a parenteral cephalosporin can be used, while for hospital-acquired infection, piperacillin/tazobactam, ciprofloxacin, or ceftazidime are recommended. For suspected vascular catheter infection or methicillin-resistant Staphylococcus aureus (MRSA) infection, teicoplanin or vancomycin should be used, with meropenem or imipenem reserved for second line treatment. Prophylactic antibiotics should not be continued once a surgical patient has returned from the theatre. Patients with febrile neutropenia receive piptazobactam, meropenem, ceftazidime or ciprofloxacin and a glycopeptide. Antifungals, usually caspofungin or liposomal amphotericin, are used if fungal infection is suspected, especially after failed antibacterial treatment. Cephalosporin use has declined as they have been linked with emergence of MRSA and Clostridium difficile. However, this reflects overuse and they still have a place as part of a diverse choice of antibiotics. Vancomycin and teicoplanin use has increased greatly in order to treat MRSA and line infections, but resistance remains unusual. Carbapenem use has increased rapidly with the emergence of extended spectrum beta-lactamase producing Gram-negative bacteria.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Meropenem"

1

de Groot, Anton C. "Meropenem." In Monographs In Contact Allergy, 619–21. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-307.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hrabák, Jaroslav. "Detection of Carbapenemases Using Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Meropenem Hydrolysis Assay." In Methods in Molecular Biology, 91–96. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1776-1_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cometta, A. "Monotherapy with Meropenem versus Combination Therapy with Ceftazidime plus Amikacin as Empiric Therapy for Fever in Granulocytopenic Patients with Cancer." In Febrile Neutropenia, 79–83. Berlin, Heidelberg: Springer Berlin Heidelberg, 1997. http://dx.doi.org/10.1007/978-3-642-60443-0_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Averbuch, Dina. "Bacterial Infections." In The EBMT Handbook, 311–19. Cham: Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-44080-9_36.

Full text
Abstract:
AbstractHCT patients are at risk for severe bacterial infection, the most frequent of them are bloodstream infections (BSI). The majority occur at the pre-engraftment period. Primary BSIs are mainly central line catheter-related (CRBSI) or mucosal barrier injury-associated. Secondary BSI accompanies site-specific infection (e.g., Pseudomonas aeruginosa pneumonia and BSI). GNB has become an increasingly common cause of BSI, and are associated with high mortality. Specifically, an increase in infections due to resistant GNB, such as ESBL Enterobacterales, carbapenemase-producing Enterobacterales (CPE), MDR GNB, or difficult-to-treat (DTR) Pseudomonas aeruginosa, leads to delay in appropriate therapy and increases mortality. Empirical antibiotic therapy should be started immediately when bacterial infection is suspected. It should be based on escalation/de-escalation principles reflecting the patient’s clinical condition, prior colonization or infection with resistant bacteria, and local epidemiology. Main targeted therapy options for severe infections caused by resistant GNB include: carbapenems for ESBL Enterobacterales; meropenem-vaborbactam or ceftazidime-avibactam for KPC-producing Enterobacterales; ceftazidime-avibactam for OXA-48-like-producing Enterobacterales; aztreonam plus ceftazidime–avibactam, or cefiderocol for Metallo-β-lactamases-producing Enterobacterales; ceftolozane-tazobactam for DTR Pseudomonas aeruginosa. Routine combination therapy of β-lactams with aminoglycosides/fluoroquinolone (FQ)/polymyxins for infection due to MDR GNB susceptible to β-lactam is not recommended (with a possible exception of a severe infections due to Pseudomonas aeruginosa in neutropenic patients). High-dose prolonged β-lactam infusion can maximize efficacy. Source control with CVC removal is important. Antibiotic treatment should be continued for at least 7 days until the infection is microbiologically eradicated and all clinical signs resolved, with the patient afebrile for at least 4 days. Antimicrobial stewardship aims to individualize an empirical approach to patients with suspected infection, limiting unnecessary antibiotic use, and optimizing treatment based on pharmacokinetic/pharmacodynamic principles. Infection control is crucial to limit the spread of MDR pathogens. Fluoroquinolone prophylaxis is controversial. Encapsulated bacteria (Streptococcus pneumoniae and Haemophilus influenzae) cause infection during the late post-engraftment period. Preventive measures include oral prophylaxis, IVIg, and vaccinations.
APA, Harvard, Vancouver, ISO, and other styles
5

Papich, Mark G. "Meropenem." In Saunders Handbook of Veterinary Drugs, 495–97. Elsevier, 2016. http://dx.doi.org/10.1016/b978-0-323-24485-5.00369-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

"Meropenem." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Simpson, Michelle C., and Eric G. Schaefer. "Meropenem." In Extended Stability for Parenteral Drugs, 268–71. ASHP, 2022. http://dx.doi.org/10.37573/9781585286720.133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

"Meropenem." In Extended Stability for Parenteral Drugs, 242–44. American Society of Health-System Pharmacists, 2017. http://dx.doi.org/10.37573/9781585285280.115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

"Meropenem." In Pediatric Injectable Drugs, 588–91. American Society of Health-System Pharmacists, 2018. http://dx.doi.org/10.37573/9781585285402.162.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Scholar, Eric. "Meropenem." In xPharm: The Comprehensive Pharmacology Reference, 1–5. Elsevier, 2007. http://dx.doi.org/10.1016/b978-008055232-3.62133-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Meropenem"

1

Nadeem, Iftikhar, Tejas Ingle, Masood Ur Rasool, Noor Mahdi, Syed Ata Ul Munamm, Bobbak Rabiei, Raaga Vijayabarathy, Duncan Grady, Sumita Pai, and Dorothy Grogono. "Nebulised Meropenem for prevention of Bronchiectasis Exacerbation." In ERS International Congress 2023 abstracts. European Respiratory Society, 2023. http://dx.doi.org/10.1183/13993003.congress-2023.pa2839.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Nadeem, I., T. Ingle, M. Ur Rasool, N. Mahdi, SA Ul Munamm, B. Rabiei, R. Vijayabarathy, D. Grady, S. Pai, and D. Grogono. "P114 Nebulised meropenem for prevention of bronchiectasis exacerbation." In British Thoracic Society Winter Meeting 2023, QEII Centre, Broad Sanctuary, Westminster, London SW1P 3EE, 22 to 24 November 2023, Programme and Abstracts. BMJ Publishing Group Ltd and British Thoracic Society, 2023. http://dx.doi.org/10.1136/thorax-2023-btsabstracts.266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Fouad Ali, Layla. "Antimicrobial Effect of Gaultheria Procumbens On Multidrug Resistant Bacteria Causing Wound Infections." In IX. International Scientific Congress of Pure, Applied and Technological Sciences. Rimar Academy, 2023. http://dx.doi.org/10.47832/minarcongress9-27.

Full text
Abstract:
Worldwide, a fast rise of resistant bacteria threatens the effectiveness of antibiotics, so alternatives should be used to overcome this serious problem. In this study a plant extract was used against multidrug resistant bacteria. Eight Klebsiella pneumonia and eight Staphylococcus aureus isolates were obtained from wounds infections. They were isolated and identified by biochemical tests and confirmed by using Vitek-2 test. The plant Gaultheria procumbens was extracted by. Susceptibility test was performed for nine antibiotics against all 16 isolated bacteria, this study brings to light that Klebsiella pneumonia isolates were 100% resistant to most antibiotics but they were sensitive with 12.5%, 75% and 75% to clindamycin, imipenem and meropenem respectively, while Staphylococcus aureus isolates were sensitive with 25% to imipenem and meropenem only. Minimal Inhibitory Concentration was assessed by using microtiter plate for plant extract and meropenem to all isolates. The plant extract subMICs were used against biofilm formation in Klebsiella pneumonia and Staphylococcus aureus isolates. Biofilm inhibition was calculated for each isolate, furthermore, biofilm formation was reduced in most Staphylococcus aureus isolates more than in Klebsiella pneumonia isolates
APA, Harvard, Vancouver, ISO, and other styles
4

Saeed MOHAMMED, Luma. "STUDY THE ANTIBACTERIAL ACTIVITY OF ALCOHOLIC EXTRACT OF ALLIUM SATIVUM ON PSEUDOMONAS AERUGINOSA AND COMPARE WITH SOME ANTIBIOTICS." In V. International Scientific Congress of Pure, Applied and Technological Sciences. Rimar Academy, 2022. http://dx.doi.org/10.47832/minarcongress5-3.

Full text
Abstract:
Twenty isolate of P.aerugiosa isolated from Baghdad hospitals identified morphologically and biochemical tests then vitek system.Disk diffusion method carried out to determined the sensitivity of bacterial isolates to different antibiotics like amoxicillin,ciprofloxacin, meropenem and cefotaxim by using Muller-Hinton agar, the results showed that 100% of isolates had resistance to amoxicillin,40% of resistance to cefotxim, 20% of resistance to ciprofloxacin and meropenem. Agar well method used to determined the minimal inhibitory concentrations for alcoholic extract of Allium sativum which prepared by using aqueous ethanol by soxhlet extractor ,it had inhibition effect in 50, and 25 mg/ml, the diameter of inhibition zone on agar were 15-9 mm.
APA, Harvard, Vancouver, ISO, and other styles
5

Abidi, Emna, Liaquat Ali, Islam M. Ghazi, Wael Rabeh, Jihad Mallat, Fadi Hijazi, and Wasim S. El Nekidy. "Pharmacokinetics of Meropenem and Colistin in a Hemodialysis patient." In ASPET 2024 Annual Meeting Abstract. American Society for Pharmacology and Experimental Therapeutics, 2024. http://dx.doi.org/10.1124/jpet.240.130548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Rammadan ABDUL, Fatima, Ihsan Ali RAHEEM, and Batool Abd Al Ameer BAQER. "DETECTION OF BIOFILM FORMATION AND RESISTANCE TO SOME ANTIBIOTICS OF ESCHERICHIA COLI." In VI.International Scientific Congress of Pure,Applied and Technological Sciences. Rimar Academy, 2022. http://dx.doi.org/10.47832/minarcongress6-19.

Full text
Abstract:
The study included twenty isolates of Escherichia coli isolated from different disease samples. It was diagnosis by microscopic methods, culture and biochemical tests and confirmed by Vitek 2 system. The ability of the isolates to produce protease showed that (9) isolates out of a total of (20) isolates with a percentage of 45% were protease -producing and 55% not producing. Biofilm formation by MTP method (15) isolates showed a percentage of 75% of a positive result for biofilm formation, while the percentage of negative isolates was 25%. The sensitivity study was conducted for the isolates against five antibiotics, and it was found that the isolates have multi drug resistance. All clinical isolates of E.coli were shown ( 100 %) resistant to piperacillin and ceftazidime. Bacteria for the rest of the antibiotics showed the least resistance to meropenem . All ten isolates were subjected to a beta-lactamase production test. Six were enzyme-producing, while four were non-enzyme producing. In addition, the minimum inhibitory concentration (MICs) for isolates were determined to five antibiotics included (Piperacillin, Ceftazidime, Azithromycin, imipenem and meropenem). The values of (MICs) for the two antibiotics ranged between (64-512) µg/ml, Piperacillin and Ceftazidime, While the meropenem(MIC) value ranged between(4-32) µg/ml
APA, Harvard, Vancouver, ISO, and other styles
7

Idoate, AI, and A. Aldaz. "4CPS-059 Effectiveness of meropenem treatment in critical patients: pharmacokinetic study." In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Johnson, Jack, Stephen Hawser, Robert Badal, Meredith Hackel, Daryl Hoban, Samuel K. Bouchillon, Brian Johnson, and Michael Dowzicky. "Meropenem Resistant Klebsiella Pneumoniae In The USA: Data From T.E.S.T. 2009." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a3356.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Idoate, AI, A. Aldaz, I. Aquerreta, and A. Ortega. "4CPS-045 Cost effectiveness analysis of meropenem dose optimisation in critical patients." In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.146.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Butzer, Sarina, Norma Jung, Seraina Duda, and Katrin Mehler. "Rückgang des Meropenem Verbrauchs bei Frühgeborenen mit Pneumoperitoneum nach Implementation eines adaptierten Behandlungspfades." In Abstracts zur 49. Jahrestagung der Gesellschaft fär Neonatologie und Pädiatrische Intensivmedizin (GNPI). Georg Thieme Verlag KG, 2023. http://dx.doi.org/10.1055/s-0043-1769388.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Meropenem"

1

Ai, Ming-Ying, Wei-Lun Chang, and Chia-Ying Liu. Mortality of Continuous infusion versus intermittent bolus of Meropenem: A System Review and Meta-analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2023. http://dx.doi.org/10.37766/inplasy2023.11.0035.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Maraolo, Alberto Enrico, and David SY Ong. Colistin plus meropenem versus colistin alone for invasive infections caused by Carbapenem-Resistant Acinetobacter baumannii: a rapid systematic review of randomized controlled trials using Bayesian meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0055.

Full text
Abstract:
Review question / Objective: What is the benefit stemming from meropenem add-on treatment to colistin against Carbapenem-Resistant strains of Acinetobacter baumannii? Condition being studied: Invasive infections caused by extensively drug-resistant (XDR) Acinetobacter baumannii, specifically carbapenem-resistant Acinetobacter baumannii (CRAB), are associated with high mortality above 50%, especially in critically ill patients. Often colistin is the only active agent in vitro and, although its safety issues, remains the cornerstone of therapy. Nevertheless, considering the relevant mortality rate when resorting to colistin alone, an intriguing idea is to exploit the potent in vitro synergy of colistin when combined with carbapenems.
APA, Harvard, Vancouver, ISO, and other styles
3

Bezerra, Alexandre Sacchetti, Flavia Altheman Loureiro, Carla Maria Pasquareli Vazquez, Afonso Cesar Polimanti, and Rafi Felicio Bauab Dauar. Empiric Treatment of Foot Infection in Patients with Severe Diabetes. Science Repository, December 2021. http://dx.doi.org/10.31487/j.jicoa.2021.04.04.

Full text
Abstract:
Background: Despite being treated with antibiotics of broad spectrum recommended by International Consensus, severe diabetic patients with lower limb infection do not present a positive clinical evolution during empirical treatment. This study’s bacterial profile was analysed and compared with other worldwide hospital centers. Objective: To confirm the need of an individualized empirical treatment for severe diabetic patients with foot infection. Methods: Retrospective analysis of cultures and antibiograms of severe diabetic patients admitted by foot infection. Results: The results were consistent with the socioeconomic realities of developing countries. Gram-negative bacteria (52,11%) were present in most bone cultures. Results presented a high incidence of Enterococcus faecalis in both gram-positive (21,2%) and polymicrobial (34,7%) samples. Bacterial resistance with the use of ordinary antibiotics in the statistical analysis was high. Conclusion: The community infections should undergo broad spectrum empirical therapy combining amikacin (80,43%) or meropenem (72,00%) with gram-negative and vancomycin (100%) or teicoplanin (90,00%) or linezolid (74,19%) with gram-positive.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Meropenem' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography